Podcasts about wegovy

The Menopause Solution with Dr. Lauren Fitzgerald What was the black box warning? Why was it there? Why is it now gone? (2:09) An interesting symptom of perimenopause. (8:12) Progesterone will change your life! (9:52) The importance of monitoring your thyroid levels and the 10 most common low-thyroid symptoms. (14:20) Testosterone for women. (22:57) Her main issue with primary care doctors. (27:14) The role of peptides in her practice. (30:01) The buy-in. (30:47) Ranking the various applications of testosterone. (33:39) The BIG myths surrounding HRT. (36:03) It's not a business, it's a mission. (40:26) GLP-1s: Incredible tools when used appropriately. (41:40) Normal isn't OPTIMAL. (45:27) The missing element for MOST people. (55:51) Related Links/Products Mentioned Visit Pre-Alcohol by ZBiotics for an exclusive offer for Mind Pump listeners! ** Promo code MINDPUMP25 for 15% off first-time purchasers on either one-time purchases (3, 6, 12-packs) or subscriptions (6, 12-pack) ** MAPS 15 FORTY PLUS 50% half from Dec. 14-20th. Code DECEMBER50 at checkout. Mind Pump Store FDA to Remove 'Black Box' Warnings From Menopause Hormone Therapy. Here's Why. The WHI Study: How Misinterpretation of Hormone Therapy Data Hurt Women's Health Welcome to the 'menodivorce'. Why women aren't sweating marriage in a sea of hot flashes Estrogen Matters: Why Taking Hormones in Menopause Can Improve and Lengthen Women's Lives -- Without Raising the Risk of Breast Cancer Mind Pump #2502: Hormone Therapy for Aesthetics With Dr. Lauren Fitzgerald Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Muscle Mommy Movement Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned LAUREN FITZ, M.D. (@drlaurenfitz) Instagram Website Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

Since Novo Nordisk launched Wegovy in 2021, it has dominated the fast-growing market for slimming drugs. Now a new jab is eating into the Danish firm's success. Why a slang expert thinks the first word humans ever uttered may have been a profane one. And why British sheep have got happier. Listen to what matters most, from global politics and business to science and technology—Subscribe to Economist Podcasts+For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.  Hosted on Acast. See acast.com/privacy for more information.

SpaceX IPO coming – huge increase in valuation over past 3 months Happy Hanukah – Eight Crazy Nights Now Kevin AND Kevin PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Last Chance for CTP Cup 2025 participants - Happy Hanukah - Eight Crazy Nights - Sad News - Rob Reiner - Fed decision is out.... - Overdue eco reports coming this week Markets - Oracle still problematic - SpaceX IPO coming - huge increase in valuation over past 3 months - Another Bankruptcy - cleaning up is not good business - Oh my - Now Kevin AND Kevin - Weight loss game continues - One thing saved for last - a doozie... Tesla -  - All time High - Prospect of Robotaxi - Even though sales hitting multi-year lows Wall Street Never Sleeps? - Nasdaq files to extend trading to 23 hours on weekdays - Banks concerned about investor protections, costs, liquidity, volatility risks of nonstop trading - Proponents argue round-the-clock trading benefits global investors - That may create some additional volatility potential SpaceX - SpaceX aims for a potential $1.5 trillion market cap with an Initial Public Offering in 2026, which could become the largest IPO in history - July 2025 tender valuation was $400B - Dec 14th (4 months later) $800B - Starlink is the primary money winner of this deal - Tesla shares climbing even with nothing behind it - seemingly in sympathy for this IPO ---- TESLA does not have ownership of SpaceX - OH - this could be the reason....U.S. deliveries dropped significantly in November—the lowest since early 2022—but this weakness has been overshadowed by the enthusiasm for autonomy. Rob Reiner - A son of legendary Hollywood director Rob Reiner and his wife, producer Michele Singer Reiner, Nick Reiner, is being held on suspicion of murder following their deaths, according to Los Angeles Police Department Chief Jim McDonnell. He's being held on $4 million bail. - Citing law enforcement sources and family friends, ABC News reported on Monday that Nick Reiner had recently returned to live at his parents' South Chadbourne Avenue home. The move was described as a temporary arrangement intended to help him stabilize. - Not going to discuss the Truth Social post about this tragedy HEADLINE ALERT - "Copper could hit ‘stratospheric new highs' as hoarding of the metal in U.S. continues" - Copper has gone from 5.77 to 5.30 (July to today) - 6 Tops at this price since 2011 - Not seeing this as per the headline - seems like a Hunt Brothers special from the 1980s - CORNERING THE MARKET ---1980 - Silver went from $11 to $50 then crashed, bankrupting the Hunt Bros - after COMEX changed rules forcing them to cover positions Bankruptcy - After 35 years, the maker of the Roomba robot vacuum filed for bankruptcy protection late Sunday night. Following warnings issued earlier this year that it was fast running out of options, iRobot says it is entering Chapter 11 protection and will be acquired by its contract manufacturer, China-based Picea Robotics. - The company says it will continue to operate “with no anticipated disruption to its app functionality, customer programs, global partners, supply chain relationships, or ongoing product support.” - Remember that Amazon  - The Amazon buyout of iRobot, maker of Roomba, was announced in 2022 for $1.7 billion but ultimately failed in January 2024 due to significant regulatory pushback, primarily from the EU, over anti-competitive concerns. -- Amazon walked away with a $94 million termination fee Fed Pick - President Donald Trump said Friday that Kevin Warsh has moved to the top of his list as the next Federal Reserve chair, though Kevin Hassett also remains in contention, according to the Wall Street Journal. - Interesting that this comes days after Hassett said that we would not let outside suggestions influence his voting - ---In addition to putting heavier weight on Warsh getting the job, Trump repeated an assertion he has made in the past that the Fed chair ought to consult the president about interest rate decisions. - Also of interest, prediction markets had Hassett at 95% probability - now it moved to 50% - big payday for people in the know. Housing Prices - Average home price is DOWN on  year-over-year basis - First time on national level since 2024 - Active listings in November were nearly 13% higher than November 2024, but new listings were just 1.7% higher --- Houses are on market longer - - Prices in Austin, Texas, are down 10% from last year; in Denver, they're down 5%, according to Parcl Labs. Tampa, Florida, and Houston both saw prices fall 4%, and Atlanta and Phoenix saw price decreases of 3%. More Hosing Related -  Zillow shares plunged more than 9% on Monday on worries that the online real estate platform could have a big new competitor: Google Search. - Google appears to be running tests on putting real estate sale listings into its search results. Overdue Eco  - Black Hole - The U.S. Bureau of Labor Statistics on Tuesday releases its long-awaited combined employment reports for October and November, but a number of key details will be missing after the government shutdown prevented data collection, including October's unemployment rate, resulting in the first-ever gap in that critical data series since inception in 1948. - NICE JOB GANG! - Some of the data will be estimated. - It said it would not publish the headline CPI number or the so-called core CPI, which strips out the volatile food and energy components, for October. "BLS cannot provide specific guidance to data users for navigating the missing October observations," the agency said. Some Updates - Some info coming in are estimates - some delayed - Unemployment at 4.6% - Latest report shows +64,000 added - ISM Manufacturing and Non-manufacturing - both slowed over the last month The Fed - Meanwhile the Fed cuts rates.... - A Federal Reserve split over where its priorities should lie cut its key interest rate Wednesday in a 9-3 vote, but signaled a tougher road ahead for further reductions. - The FOMC's “dot plot” indicated just one more reduction in 2026 and another in 2027, amid considerable disagreement from members about where rates should head. - In addition to the rate decision, the Fed also announced it will resume buying Treasury securities. The central bank will start by buying $40 billion in Treasury bills, beginning Friday. - Markets were all over the place on this as it was a little confusing at first - then it seemed that everyone loved (for one day) - Why is the Fed moving up Treasury purchases to "immediately" from a few months from now? - AND - dissension ! A larger group  that usual of regional Fed bank presidents signaled they opposed the cut, and six policymakers said the benchmark federal funds rate should end 2025 in a range of 3.75% to 4%, suggesting they opposed the move. - Long bonds have not moved at all on this news. Costco Earnings - Costco beat Wall Street's fiscal first-quarter sales and revenue expectations. - Sales rose 8.2% and digital sales jumped 20.5% compared with the year-ago quarter. - Costco surpassed Wall Street's quarterly expectations and posted year-over-year sales growth of 8.2% as the retailer attracted more digital sales and opened new locations. - Earnings per share: $4.50 vs. $4.27 expected - Revenue: $67.31 billion vs. $67.14 billion expected - Costco does not provide year ahead guidance - Shares down from a recent high of $855 Costco Fun Facts - About 4.5 million pies were sold in the three days before Thanksgiving, which is equivalent to roughly 7,000 pies per warehouse. -  These were bakery pies (e.g., pumpkin, apple), - Costco had more than $250 million in non-food online orders on Black Friday, a record for Costco's U.S. e-commerce business. - Approximately 358,000 whole pizzas were served at Costco's U.S. food courts, a 31% jump from last year. (500 pizza's per store) Fat No More - Retatrutide - Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. - In a 48-week Phase 2 study, participants on the highest dose lost an average of 24% of their body weight. - Recent Phase 3 results showed patients on the highest dose lost an average of 28.7% of their body weight after 68 weeks. - The trials also showed improvements in related health conditions, including knee osteoarthritis pain, blood pressure, and liver fat - This triple action is what makes retatrutide potentially more effective for weight loss than existing medications like Zepbound (tirzepatide), which targets two receptors, or Wegovy (semaglutide), which targets only one. Paypal - PayPal Holdings Inc. applied to become a bank in the US, looking to take advantage of the Trump administration's openness to financial-technology companies entering the banking system. - The payments-focused firm submitted applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions to form a Utah-chartered industrial loan company, PayPal said in a statement Monday. - If approved, PayPal Bank would help the firm bolster its small-business lending capabilities, according to the statement, which said the company has provided access to more than $30 billion in loans and capital since 2013. Ford - Management Confused - Instead of planning to make enough electric vehicles to account for 40 percent of global sales by 2030—as it pledged just four years ago—Ford says it will focus on a broader range of hybrids, extended-range electrics, and battery-electric models, which executives now say will account for 50 percent of sales by the end of the decade. - The automaker will make hybrid versions of almost every vehicle in its lineup, the company says. - All in on EVS cost them -  Ford expects to record about $19.5 billion in special items, mostly during the fourth quarter. ---- The charges are related to a restructuring of its business priorities and a pullback in its all-electric vehicle investments. Australia - Australia has implemented a groundbreaking ban preventing children under 16 from accessing major social media platforms like TikTok, Instagram, and Facebook, effective December 2025, to protect them from harm, with significant fines for companies failing to enforce it, though messaging apps and gaming platforms are currently exempt. - Reddit is suing - Facebook, Instagram, Snapchat, Threads, TikTok, X (Twitter), YouTube, Reddit, Kick, and Twitch are all banned for kids under 16. - Thoughts on this? Saved For Last - Of all the eye-popping numbers that Oracle Corp. published last week on the costs of its artificial-intelligence data center buildout, the most striking didn't appear until the day after its earnings press release and analyst call. - The more comprehensive 10-Q earnings report that appeared on Thursday detailed $248 billion of lease-payment commitments, “substantially all” related to data centers and cloud capacity arrangements, the business-software firm said. These are due to commence between now and its 2028 financial year but they're not yet included on its balance sheet. - That's almost $150 billion more than was disclosed in the footnotes of September's earnings update. Love the Show? Then how about a Donation? The Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing medicine — but at what cost? In this episode of The Exam Room Podcast, host Chuck Carroll sits down with Ben Urich, PharmD, PhD, to break down the real-world data behind the GLP-1 explosion. You'll learn: - How many people are actually using GLP-1 drugs - Why most users stop — and why that's starting to change - The true cost of GLP-1 medications to employers and health plans - Common and serious side effects to be aware of - Why GLP-1s are now being studied for Alzheimer's disease and addiction - What the future holds as more than 30 new drugs enter the pipeline This is a must-watch conversation for anyone considering GLP-1 medications, currently using Ozempic or Wegovy, or wondering where modern weight-loss medicine is headed next.

What No One Tells You About Life After GLP-1 Meds GLP-1 medications like Ozempic, Wegovy, and Mounjaro have changed the game for weight loss—but what happens when the prescription ends and you need a plan? This week, I'm joined by Dr. Jim Hill, leading obesity researcher and architect of the National Weight Control Registry, to uncover what really happens after GLP-1s—and how to maintain your results without spiraling into regain. We'll explore the three types of weight regain, what makes maintenance so different from weight loss, and why your body is capable of mimicking GLP-1 effects naturally—if you know how to support it. Whether you're on these meds now, thinking of stopping, or just want to protect your progress, this is a must-listen.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezRo - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________           This isn't medical advice — always talk to your doctor before making any health decisions.In this episode, we discuss the complexities of obesity, moving far beyond the simple "calories in, calories out" narrative. Our conversation unravels the latest science to distinguish between different types of obesities (e.g., metabolically healthy vs. unhealthy, visceral vs. subcutaneous fat distribution), challenging the perception of obesity as a single, uniform condition. Experts in obesity medicine and educators, we examined the landscape of collegiate obesity and nutrition education of future leaders. We dive into how the landscape of obesity treatment is being introduced to new students and practitioners. Our experts contrast modern, holistic, and evidence-based approaches with past didactic methods, emphasizing metabolic health, patient empathy, and anti-bias training.Our astute educators help Debunk GLP-1 Myths as well. A critical segment is dedicated to dismantling the misconception that weight loss on GLP-1 agonists (like Ozempic or Wegovy) is simply due to calorie restriction alone. Our experts explain the drug's mechanisms involving satiety signals, gastric emptying, and metabolic pathways, proving it is a complex hormonal and neurological intervention.Don't miss this important episode, and learn how the future of obesity treatment is being shaped.Professional Guest:Leah D. Whigham, PhD, FTOSProfessor, Department of Nutritional SciencesDr. Nik DhurandharPaul W. Horn Distinguished ProfessorHelen DeVitt Jones Endowed ChairChair, Department of Nutritional SciencesAssociate Dean for Innovation, College of Health and Human SciencesTexas Tech UniversityCheck out Dr Dhurandhar's Fat-loss Diet book at the below linkhttps://www.amazon.com/Dhurandhars-Fat-loss-Diet-Nikhil-Dhurandhar/dp/9352770307______________________________________________________________________Send us Fan Mail! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Can you get rhabdomyolysis (rhabdo) from taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro(tirzepatide)? Here are the reports of people getting rhabdo after taking these medications, including how much they took, how high their creatine kinase level were, and what happened. Rhabdo after taking glucagon-like peptides appears to be rare but this is still a side effect people should be aware of. View the video below to see the reports yourself.Referencehttps://youtu.be/NlLTIsXJ860 Read My Rhabdo BookAmazon https://amzn.to/4aRPnu4 (affilate link) Consultations https://supplementclarity.com/private-consultations/  Connect With MeaffiliateSupplementClarity.comYouTubeTiktok   About  I've been sorting nutrition facts from fiction since the 1990s and helping people understand dietary supplements, using clinical research as my litmus test. I am unbiased. I analyze the research so you don't have to.  I wrote the first book about exercise-induced rhabdomyolysis.I have an MS in exercise science and a BS in biology & chemistry.   Disclaimer Episodes are for information only. I'm NOT a medical doctor. NO medical advice is given or implied. ALWAYS consult your physician for the best health advice for you. I participate in theAmazon Associates program which means if you click on a link to amazon and make a purchase, I may make a small commission at no extra cost to you.

Holiday urgency is real, whether you are trying to squeeze into your jeans or squeeze in those last few deals, and on this Bathroom Break Daniel Murray pulls Jay Schwedelson into a fast, funny riff on how to make that urgency actually pay off. They get into a wild "ate through the shot" Wegovy story, then flip it into simple, budget friendly tactics that push people to buy or opt in without feeling gimmicky. From DTC countdown discounts to B2B content that literally expires, you get plug and play ideas you can steal before the year is over.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(01:08) Jay admits he tried Wegovy expecting magic, then laughs about how he "ate through the shot" and ended up just eating less instead.(02:30) Daniel calls out how much money Jay wasted on the shot before pivoting into the real topic of using urgency to close year end revenue and email goals.(03:22) Daniel breaks down Set Active's "Set Miss" promo and why shrinking discount windows instantly force shoppers to make a decision.(05:26) Jay shares a dead simple B2B play where you put a countdown on how long a guide is available, then actually remove it from your resources page.(07:11) They brainstorm a "12 days of content" idea where every day a new curated asset drops and then expires to rapidly grow your email list.(08:23) The chat drifts into holiday party avoidance, sweatpants vs real pants, and Jay getting officially banned from wearing his hat backwards at 50.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/

https://www.otplinks.com 0:00 Welcome & today's focus: Retatrutide and “chasing the biggest number” 1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping 2:10 How Dave first heard about retatrutide (work trip, early phase 1 data) 3:35 Flashback clip: early excitement about retatrutide phase 3 trials 4:40 Why this new retatrutide data feels different for obesity medicine 5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population 7:00 Headline results: 28.7% average weight loss, surgery-level efficacy 8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates) 11:05 What “efficacy estimate” really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From “just make the scale go down” to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor” 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s aren't the same as injectable peptides 48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned 51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

durée : 00:45:58 - On n'arrête pas l'éco - par : Alexandra Bensaid - Au menu ce samedi : un débat sur le projet d'euro numérique, un détour par Madrid, un reportage sur le commerce illicite de médicaments contrefaits... Et un entretien avec le patron France de Novo Nordisk, dont les traitements Ozempic ou Wegovy affinent les silhouettes et transforment l'économie. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

durée : 00:11:23 - L'Invité d'On n'arrête pas l'éco - Les traitements anti-obésité, en pleine vogue depuis deux ans, redessinent les silhouettes... mais aussi l'économie, des comptes de la Sécu jusqu'aux portions dans les restaurants. Entretien avec Etienne Tichit, le patron France de Novo Nordisk, le laboratoire derrière le Wegovy et l'Ozempic. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Welcome to Ozempic Weightloss Unlocked, the podcast that unpacks how this medication is reshaping health, lifestyle, and the future of weight management.Ozempic is a brand name for semaglutide, a medication originally approved to treat type two diabetes. It mimics a gut hormone that helps the pancreas release insulin, lowers blood sugar, slows stomach emptying, and signals the brain to feel full sooner. The result for many people is significant weight loss, which is why a higher dose of the same drug is sold separately for obesity under the name Wegovy, according to the United States Food and Drug Administration and the National Institutes of Health.Because of this dual effect on blood sugar and appetite, Ozempic has become a cultural phenomenon. Listeners hear about it from celebrities, social media, and even coworkers, but medical experts keep stressing one key point. These are prescription drugs meant for people with type two diabetes or with obesity and related health risks, not quick fixes for casual weight loss. Major medical groups such as the American Diabetes Association and the Obesity Society are pushing to protect access for patients who truly need them.Recently, attention has shifted to what happens beyond the number on the scale. Some people lose not only fat but also muscle, which can affect strength, mobility, and metabolism. Researchers at Karolinska Institutet and Stockholm University, writing in the journal Cell, report a new tablet treatment that increases fat burning and improves blood sugar while preserving muscle mass, and it works very differently from Ozempic. Instead of acting on appetite in the brain, it targets skeletal muscle directly, and early trials suggest it may be used alone or even combined with a drug like Ozempic in the future.At the same time, the competition in obesity medicine is heating up. Eli Lilly has developed a so called triple hormone drug called retatrutide that activates three receptors instead of one. Eli Lilly and coverage from outlets like ABC News report that in a large trial of people with obesity and knee osteoarthritis, participants on the highest dose lost nearly twenty nine percent of their body weight on average and saw a big drop in knee pain. While retatrutide is still in clinical trials and not yet approved, it shows how the field is racing to go beyond the results seen with Ozempic alone.For listeners, this rapid progress brings both excitement and responsibility. These medications can improve blood sugar, reduce cardiovascular risk, and help treat diseases linked to excess weight, but they can also cause nausea, vomiting, diarrhea, and in some cases gallbladder or pancreatic issues. Long term use may require monitoring of muscle mass, nutrition, and mental health. Physicians are now talking more about pairing these drugs with resistance training, adequate protein, and psychological support so that weight loss does not come at the cost of strength or well being.Ozempic has also raised bigger questions. Who should get access when supplies are limited. How will insurance handle long term therapy for what is often a chronic condition. And what happens if a person stops the medication and the hunger comes back. Early data suggest that for many, maintaining results may require ongoing treatment, much like blood pressure medicine.On Ozempic Weightloss Unlocked, we will keep tracking all of this. From new trials and pill based options, to combination therapies, insurance changes, and real world stories of how life looks on and off these medications, our goal is to give you clear, balanced information so you can have better conversations with your own health care team.Thank you for tuning in, and remember to subscribe so you never miss an update on the evolving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

You've seen it all over social media. Everyone's talking about GLP-1's. Maybe you've heard the brand names—Ozempic, Wegovy, Mounjaro—and wondered, "What exactly is this, and why are so many women suddenly using it?" If you're in perimenopause and noticing weight gain despite doing everything "right," battling constant cravings, or feeling like your body is working against you... this episode is for you.Dr. Katashia is back on the podcast to break down exactly what GLP-1's are, how they work, and why they might be a game-changing tool for women navigating the hormonal chaos of midlife. She shares her own experience using them at 48, the side effects you need to know about, and the critical steps to take before you even consider starting. This isn't about taking shortcuts—it's about understanding your options and finally getting the support your body needs during this transition.In this episode we explore:The real purpose of your inner autumn — and how ignoring it creates hormone chaosWhat happens when you stop pushing through PMS and start listening to your bodyHow I cycle sync my entire business with the inner seasonsA behind-the-scenes look at my 2025 autumnTune in next week were we dive into Part 2 of this conversation.Resources:Dr Katashia's Website - drkatashia.comFollow Dr. Katashia on Instagram: @drkatashiaCheck her out on Facebook: Dr. Katashia Wellness CollectiveJoin my Hormone Unfiltered NewsletterAbout KateKate Nguy is the founder of Shee Revival and a Certified Hormone Health Practitioner and Cycle-Syncing Strategist who helps busy women in their 30s and 40s balance their hormones and reclaim their energy. Specializing in the hormonal ups and downs of midlife—from PMS and perimenopause to burnout and cortisol overload—Kate guides women to feel at home in their bodies and live in sync with their natural cycles.. Through cycle syncing, hormone hacks, and nervous system regulation, Kate empowers women to rebalance their hormones, reconnect to their bodies, and revive the vibrant, grounded version of themselves underneath the overwhelm.Tune in now and join the movement toward better hormone health!Follow me @hormoneswithkate on Instagram for more insights, tips, and support!

Mind Pump Fit Tip: Hacks to increase daily activity for fat loss and health. (2:55) Training and fueling your teenage kids, and labor-driven school projects. (20:16) The birth of AI consciousness. (26:01) Mind Pump Recommends the Age of Disclosure on Prime Video. (32:28) Thanksgiving festivities. (43:36) Adam updates on the audience on how he is recovering from his Kratom withdrawal. (47:29) How dumb bureaucracy is. (1:02:06) #ListenerCoaching call #1 – Could you use any MAPS programs while taking a GLP-1 medication? (1:05:12) #ListenerCoaching call #2 – The best MAPS program for a stay-at-home mom who is not getting great sleep. (1:14:19) #ListenerCoaching call #3 – How realistic is it to achieve that level of muscle development from a home gym setup? (1:21:51) #ListenerCoaching call #4 – A new trainer wanting advice, how to coach reverse dieting to my clients like a pro. (1:29:08) Related Links/Products Mentioned Get Coached by Mind Pump, live! Visit https://www.mplivecaller.com  Visit Crisp Power for an exclusive offer for Mind Pump listeners! ** Code MINDPUMP10 for 20% off. Give your snack game a serious upgrade. Crisp Power Protein Pretzels deliver super crunchy and delicious snacks that are up to 28g of protein, low carb, zero sugar, and high in fiber! ** Visit Legion Athletics for the exclusive offer for Mind Pump listeners! ** Code MINDPUMP Buy one, get one 50% off for new customers, and 20% cash back for returning customers! ** MAPS 15 STRONG 50% half from Dec. 7th-13th. Code DECEMBER50 at checkout. Mind Pump Store Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts Walking 8,000 steps just 1-2 days a week linked to significant health benefits Bret Weinstein on the Birth of AI Consciousness | JRE The Age of Disclosure - Prime Video An Alarming Decline in the Nutritional Quality of Foods California declares kratom illegal, raids stores in Sacramento and San Diego Visit Seed for an exclusive offer for Mind Pump listeners! ** Code 20MINDPUMP for 20% off your first month of Seed's DS-01® Daily Synbiotic. ** Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Mind Pump #2572: Only 15 Minutes a Day to Build Muscle & Burn Fat Mind Pump #2530: Why All Women Should Take Creatine Ask Mind Pump Trainer Bonus Series Episode 2: Diet & Exercise Strategies That Work AND Clients Love The Complete Reverse Dieting Guide (E-Book) - Biolayne Store Elite Trainer Academy – Podcast Schedule a Reverse Dieting Strategy call with a Mind Pump coach Mind Pump #2690: The NEW DIET Everyone Is Using For Fat Loss Mind Pump Podcast – YouTube Mind Pump Free Resources People Mentioned Bret Weinstein (@bret.weinstein) Instagram Andrew Huberman, Ph.D. (@hubermanlab) Instagram Layne Norton, Ph.D. (@biolayne) Instagram

Doctor Mau Informa ®️#drmauinforma 

Send us a textIn this next “Best of 2025” series, I'm bringing back a popular episode featuring my amazing husband, Dr. Taylor Brueseke. Together, we break down Wegovy, Ozempic, and Mounjaro to clear up common misconceptions. Dr. Brueseke explains how these medications work, what they're intended for, and the potential side effects, while I share my personal experience to give you a real-life perspective on using them. Whether you're a healthcare professional, someone navigating your own health journey, or simply curious, this episode will help you better understand these treatments. Let's sort through the confusion and get to the truth about Wegovy, Ozempic, and Mounjaro. Let's dive in!Find show notes at bicepsafterbabies.com/395Follow me on Instagram and Tiktok!Links:Episode 317: I Was Wrong About Wegovy, Ozempic, and Mounjaro with Dr. Taylor Brueseke

Book a FREE functional health discovery call HERE. If you've been hearing the buzz about Ozempic, Wegovy, Mounjaro, or other GLP-1/GIP medications, you're not alone. But there's so much more to this conversation than weight loss. In this episode, Tanya breaks down the real science behind GLP-1 receptor agonists — what they are, how long they've been around, and the growing research that shows benefits far beyond the scale. From heart and kidney protection to inflammation reduction and body composition support, Tanya explains what midlife women need to know before jumping on the bandwagon. She also shares her personal journey exploring micro-dosing peptides (including tirzepatide and NAD+) — what she's learning, what's working, and how she's helping women make informed, safe, and personalized decisions through trusted telemedicine partnerships. Whether you're considering GLP-1s, curious about peptides, or simply trying to build energy and longevity in midlife, this episode will help you understand the research, the real benefits, and the importance of building your health on solid foundations. You'll Learn: What GLP-1 receptor agonists are and how they work in the body The long-term research behind GLP-1s — including heart, kidney, and liver health benefits What “micro-dosing” really means (and what we don't yet know) How peptides like tirzepatide and NAD+ may support energy, inflammation, and recovery Why foundational health habits — nutrition, muscle, rest, stress regulation — matter more than any injection or supplement Practical, real-world takeaways for midlife women seeking sustainable health and vitality Disclaimer: This episode is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare provider before beginning or changing any health protocol or medication.   I hope this episode blesses you! Xoxo, Tanya Episode Resources: Episode Catalog   My trusted Supplement Dispensary: Aligned Vitality Fullscript Dispensary My trusted Telehealth Peptide Provider:  EllieMD_Tanya Engesether *I do get a small commission when you use one of the above affiliate links. 3 Ways To Connect With Me: 1️⃣COACHING: Are you READY to Lead Well, Live Well and BE Well? Book a FREE discovery call with me to find out more about functional health coaching. It's the accountability and guidance you need to reclaim your health and happiness! ➡︎ https://alignedvitalityhealth.com/coaching   2️⃣ FACEBOOK: Become part of our Supportive Facebook Group. Connect, share, and learn with others navigating life and leadership ➡︎ https://alignedvitalityhealth.com/community   3️⃣ CONTACT: Leave me a question or comment ➡︎ https://alignedvitalityhealth.com/contact   "Yes! Finally, a podcast helping others become the thriving leaders they're meant to be outside of hustle-culture! This is an amazing resource! Thank you so much for sharing and helping us become Spirit-driven, peaceful leaders!"    If you can relate, please consider rating and reviewing my show! It helps me reach more people – just like you – to help them change their future. Don't forget to follow the show so you don't miss any episodes! And, if you're feeling really generous, I'd be SO honored if you would share this podcast with someone.   Click here to view our privacy policy.   Reminder:  The information you hear on this show is not meant to diagnose, treat, cure or prevent disease.  It is for educational purposes only. Always consult with your own health practitioner before you make any changes to your health.

2025: The Year America Got Thinner — But Not Healthier | Media Power Grabs & Cancer Truths 2025 is being called “the year America shed” — with more people losing weight than ever thanks to fad diets, Ozempic, Wegovy, Zepbound, and every quick-fix trend imaginable. But here's the shocking truth: Americans may be getting thinner, but not healthier. Why? Today we break down the real reasons behind the wellness illusion. Then, a massive story almost no one is paying attention to: the brewing Warner Bros. takeover battle. Donald Trump, backed by Saudi money and his son-in-law Jared Kushner, is pushing for a hostile takeover to compete with (and control) Netflix. What's the motive? What does it mean for media, entertainment, and democracy? We dig into the power dynamics behind the scenes. Plus — new, surprising research on cancer detection asks a provocative question: Should all cancers be found? The answer isn't what you think. The Karel Cast is funded by your support at patreon.com/reallykarel. Watch, like, comment, and subscribe at youtube.com/reallykarel. Listen on all major platforms: Apple Music, Spotify, iHeartMedia, Spreaker, and more. Catch the show Monday through Thursday at 10:30 AM PST, with daily clips on TikTok and Instagram. Karel is a history-making broadcaster based in Las Vegas with his service girl, Ember — bringing bold commentary, big stories, and unfiltered truth. #TheKarelCast, #2025Trends, #OzempicCulture, #WeightLossTruth, #Wegovy, #Zepbound, #AmericanHealthCrisis, #MediaTakeover, #WarnerBrosDeal, #TrumpNews, #JaredKushner, #SaudiMoney, #NetflixWar, #CancerResearch, #HealthMyths, #PoliticalCommentary, #NewsAnalysis2025, #LasVegasCreator, #LGBTQCommentator, #PodcastLife https://youtube.com/live/NPftX-i5_EU

Welcome to Ozempic Weightloss Unlocked, the show where we unpack how this powerful medication is reshaping medicine, health, and everyday life.Today we are diving into the very latest science on semaglutide, the drug sold as Ozempic for diabetes and Wegovy for obesity, and what new research means for listeners who are using it or thinking about it.A new real world study in the journal Current Medical Research and Opinion followed people on once weekly semaglutide for two full years. Researchers found that on average, patients lost about thirty nine pounds, or nearly seventeen percent of their body weight, and most kept that weight off over the full twenty four months. People also saw improvements in blood pressure, cholesterol, blood sugar, and many moved from prediabetes or diabetes back to normal blood sugar levels. That is important, because it confirms that Ozempic is not just a quick fix but can be part of long term weight management when it is continued and combined with lifestyle changes.At the same time, doctors are getting clearer about downsides. A recent analysis from researchers in Utah, reported by Ladbible, warned that Ozempic related weight loss can come with a drop in lean mass, including muscle, of around ten percent. That is less loss than some earlier crash diets have caused, but it still matters. Losing muscle can weaken strength, slow metabolism, and be especially risky for older adults. Experts now stress pairing Ozempic with enough protein, resistance exercise, and medical follow up to protect muscle.For older listeners, the Association of American Medical Colleges reports that trials suggest these drugs can be safe and effective after age sixty five, but that adults over seventy five were rarely studied. Clinicians are urging extra caution in seniors because they are more prone to side effects like nausea, dehydration, and muscle loss, and they may already be on multiple medications.Researchers are also uncovering surprising new uses. Memorial Sloan Kettering Cancer Center reports that glucagon like peptide drugs such as Ozempic may help people with obesity reduce their risk of several cancers linked to excess body fat, including breast and colon cancer. In an early study in breast cancer patients, these medications helped counteract the weight gain that often comes with treatment, which could improve long term heart and cancer outcomes if confirmed in larger trials.Scientists are even exploring effects on brain health. Imperial College London recently showed that another drug in the same family, called liraglutide, slowed brain shrinkage and cognitive decline in people with Alzheimer disease over one year. Patients on liraglutide had almost fifty percent less brain volume loss in key memory areas compared with placebo, and their thinking declined about eighteen percent more slowly. While this was not Ozempic itself, it suggests this whole class of drugs might play a future role in protecting the brain, and large phase three trials are now underway.There is also growing attention on mental health. Think Global Health highlights that when people lose even a modest amount of weight and improve metabolic health, their risk of depression and anxiety often falls. Some patients report better mood and fewer food cravings on Ozempic, while a small number describe emotional blunting or worries about identity after major weight loss. Regulators in Europe have examined rare reports of suicidal thoughts, but the United States Food and Drug Administration has said current evidence does not show a clear causal link. Still, it is essential for anyone on these medications to check in regularly with their care team about mood and mental health, not just the number on the scale.Finally, researchers are already working on what might come next. Scientists at Karolinska Institutet in Sweden recently reported a new experimental pill that burns fat by acting directly on muscle metabolism instead of appetite. In early human trials it improved blood sugar and body composition without reducing appetite or muscle mass. If it proves safe and effective, it may one day be used alone or together with drugs like Ozempic to achieve weight loss with fewer side effects.Taken together, the latest science tells us this. Ozempic and related medications can deliver major, sustained weight loss and improve heart and metabolic health. They may lower risks tied to obesity, from diabetes to some cancers, and could even have future roles in brain health. But they are not magic. Protecting muscle, supporting mental health, tailoring treatment to age, and combining medication with nutrition, movement, and sleep are all crucial.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, be sure to subscribe so you never miss the latest updates on Ozempic, weight loss, and health.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

This episode is brought to you by Joi & Blokes, Troscriptions, and Caldera Lab. In this episode of Ever Forward Radio, registered dietitian Ashley Koff, RD breaks down the truth behind GLP-1 medications like Ozempic and Wegovy, reframing them not as magic weight-loss shots but as hormone replacement therapies that reveal how dysfunctional most people's "weight-health hormones" have become. Ashley shares how digestion, nutrient status, genetics, and modern environmental pressures diminish the body's natural ability to regulate appetite, cravings, metabolism, and fat distribution — and why GLP-1 drugs can offer clarity but not a cure unless the underlying issues are addressed. She dives into muscle preservation, the limitations of BMI, the importance of fat-mass vs. scale weight, the root-cause approach to sustainable weight health, and what the future of GLP-1s means for generational wellness. This is a powerful conversation that blends science, personal insight, and actionable strategies to improve metabolic health — with or without medication. Follow Ashley @ashleykoffapproved Follow Chase @chase_chewning ----- 00:00 – GLP-1 hype: weight loss, risks, and whole-body benefits 02:00 – What GLP-1 drugs actually do in the body 02:20 – Understanding "weight-health hormones" 03:00 – Why society is functioning with suboptimal hormones 12:00 – Why total weight doesn't matter — muscle, fat, and bone do 14:00 – BMI is broken and misleading 15:00 – Weight regain, muscle loss, and metabolism 17:00 – Genetics, survival traits, and appetite regulation 23:00 – Root-cause approach: digestion, nutrient status, vagus nerve work 26:00 – How GLP-1s validate hormone dysfunction 28:00 – Side effects like nausea and constipation explained 30:00 – Why digestive repair is essential for long-term success 33:00 – How GLP-1s quiet obsessive thoughts, cravings, and food noise 36:00 – Supplements that support GLP-1 and weight-health hormone function 38:00 – Hop extract research and natural "GLP-1 activators" 42:00 – Limitations of natural alternatives vs. true hormone replacement 1:12:00 – Glucose spikes, CGMs, and metabolic flexibility 1:27:00 – The future of GLP-1s and redefining "obesity" 1:28:00 – Generational weight health and epigenetics 1:29:00 – Final thoughts and Ashley's Ever Forward message ----- Episode resources: Get 50% off any diagnostic labs with code CHASE at https://www.JoiAndBlokes.com/chase  Try CALM and save with checkout code EVERFORWARD at https://www.Troscriptions.com/everforward  Get 20% off the best men's skincare with code EVERFORWARD at https://www.CalderaLab.com  Watch and subscribe on YouTube Get Ashley's book on Amazon

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We share a quick life update, welcome our first guest Mike Rozanski, and clear up the Michelin Guide origin story before shifting to a focused guide on starting GLP-1 medications. Practical strategies cover injections, nausea, constipation, muscle protection, and adjusting other meds safely.• board certification in obesity medicine and motivation to destigmatise care• guest segment on Michelin guide history and Philly's recent stars• what GLP-1 meds are and how auto-injectors work• portion sizing to prevent nausea and early side effects• fiber with fluids to prevent constipation• protein targets and simple strength training to protect muscle• when to adjust blood pressure and diabetes medications• key takeaways and encouragement to start small and follow upIf you found this helpful, a review really does go a long way for a like on whatever app you're listening to us onSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you're over 60 and using GLP-1 medications like Wegovy or Zepbound, this episode could save your independence. In this episode, I reveal the hidden danger of rapid weight loss without muscle protection—and the simple strategies that keep you strong, steady, and mobile as the pounds come off. GLP-1 medications are transforming weight loss for older adults managing diabetes, high blood pressure, and joint pain. But there's a critical piece most people miss: sarcopenia. This age-related muscle loss accelerates during weight loss, putting you at risk for falls, fractures, and losing the strength you need for daily activities. Tune in to learn how to lose weight safely while protecting the muscle that keeps you independent—and why strength training, protein intake, and staying active aren't optional on this journey.   Episode Highlights: Why GLP-1 medications like Wegovy and Zepbound are game-changers for adults 60+ The connection between muscle loss, falls, fractures, and loss of independence How sarcopenia affects metabolism, blood sugar control, and bone health Protein requirements for older adults (25-30 grams per meal) Simple strength training routines you can do at home—no gym required Red flags that muscle loss is happening too fast Real patient story: turning weakness into strength on a GLP-1 journey   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration.   Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free.   The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available.   "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said.   https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including  a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear.   Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries.   Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology.   New with Dexcom G7 15 Day:  Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider. At launch, Dexcom G7 15 Day will connect with the iLet Bionic Pancreas and Omnipod® 5§§. We are working closely with Tandem and look forward to extending the launch to their customers shortly as they finalize integration. For specific information on pump compatibility and availability with the Dexcom G7 15 Day system, visit Dexcom.com/connectedpumps https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Continuous-Glucose-Monitoring-System-to-Launch-on-Dec--1-in-the-United-States/default.aspx   XX A small study of ten adults with type 1 diabetes tested Tandem's new fully closed-loop "Freedom" insulin system — and the participants put it through a real-world stress test. For 72 hours in a hotel setting, they ate heavy carb-and-fat meals, skipped all meal announcements, and didn't give any mealtime insulin boluses. The system handled almost everything automatically. Researchers said the device stayed in closed-loop mode 97% of the time and there were no incidents of diabetic ketoacidosis or severe hypoglycemia reported. While using the Freedom system, participants spent a median 61% of the day in the glucose target range — slightly higher than the 56% achieved with their usual pump at home. But the biggest improvement came overnight: time in range jumped to 96% with the closed-loop system compared to just under 70% during their home-pump week. With almost zero time spent below 70 mg/dL, researchers concluded that the fully automated Tandem system was both safe and effective even with unannounced, high-impact meals — hinting at a future of diabetes management that demands less effort from users.   XX Novo Nordisk reported promising mid-stage results for its experimental drug amycretin (AM-ee-creht-in) in diabetes patients on Tuesday. Amycretin, targets both GLP-1 and amylin hormones. In this study, it helped patients with type 2 diabetes lose up to 14.5% of their body weight over 36 weeks with weekly injections, far outperforming a placebo. The oral version delivered weight loss of up to 10.1%. Rival Eli Lilly  is surging ahead with its own amylin-based drug, eloralintide, which is advancing to late-stage testing after helping patients shed as much as 20% of their weight in a mid-stage trial. https://www.cnbc.com/2025/11/25/novos-next-gen-obesity-drug-shows-positive-results-heads-to-late-stage-testing.html XX The U.S. Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those medications compared with recent annual spending, or about $8.5 billion in net covered prescription costs. The prices go into effect in 2027, including a monthly price of $274 for Novo Nordisk's popular GLP-1 drug semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes. medicare's recent net price for Ozempic, opens new tab was $428 a month, according to an analysis published in the Journal of Managed Care and Specialty Pharmacy. Medicare put the drug's list price, before confidential rebates and discounts, at $959 a month. Based on such nondiscounted list prices, Medicare said savings on the 15 drugs ranged from 38% to 85%. The annual price negotiations were established under President Joe Biden's signature Inflation Reduction Act (IRA) of 2022. Previously, Medicare was barred by law from negotiating with drugmakers. https://www.reuters.com/business/healthcare-pharmaceuticals/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25/   XX LifeScan announced its Chapter 11 bankruptcy reorganization plan received U.S. Bankruptcy Court approval. LifeScan said it's positioned to emerge from its financial restructuring process by the end of the year. The CEO says, "This balance sheet restructuring provides a stronger foundation for LifeScan to support our base business, advance new growth strategies, and commence our journey to become one of the most comprehensive players in the glucose management space." https://www.drugdeliverybusiness.com/glucose-monitor-lifescan-emerge-from-bankruptcy/ XX An artificial intelligence (AI)-led Diabetes Prevention Program (DPP) was as effective as a traditional human-led program in achieving recommended goals for weight loss, A1c reduction, and physical activity, according to a randomized trial of adults with prediabetes and overweight or obesity. One example of a push notification: "Looks like you're at the grocery store, Rita! Want a quick list of high-fiber snacks or smart swaps to stay on track this week?" The app also provided location- and goal-based education, with gamification elements to promote engagement. Approximately one third of participants in both the AI and human-led groups achieved the primary outcome (31.7% and 31.9%, respectively). Results were consistent across sensitivity analyses and individual components of the composite endpoint. "As more AI-based programs emerge, head-to-head comparisons among different AI-DPPs will be informative. An AI-led approach will not suit everyone; some individuals benefit more from human interaction and accountability," said Mathioudakis, adding that future research should focus on best matching patients to the modalities they prefer. https://www.medscape.com/viewarticle/ai-directed-diabetes-prevention-program-effective-human-2025a1000xam XX A new study suggets metformin could help people with type 1, reducing the need for insulin.  The researchers were surprised to find that metformin did not improve insulin resistance or change blood sugar levels. This suggests that, unlike in type 2 diabetes, metformin doesn't combat insulin resistance in type 1 diabetes.   However, metformin did reduce the amount of insulin people needed to keep their blood sugar levels stable.   https://www.the-express.com/news/health/192157/diabetes-medicine-insulin-type-1 XX Beyond Type 1 launches #TheBeyondType campaign in India to combat type 1 diabetes stigma. Nick Jonas is one of the founders of Beyond Type 1, his wife, Priyanka Chopra Jonas is his partner in this new non profit. The initiative highlights inspiring individuals living with T1D and partners with local organisations to improve awareness, medical support, and community networks for affected families across the nation. India has more young people living with T1D than any other nation, yet understanding of the condition remains limited. Beyond Type 1 is partnering with grassroots organisations across high-need regions. These include HRIDAY in Delhi–NCR, Nityaasha Foundation in Pune, Gram Jyoti in Jharkhand, and SAMATVAM Trust in Bangalore—each group focusing on improving awareness, providing medical support and building stronger community networks for young people with T1D.

In this episode of Healthy Mom Healthy Baby Tennessee, Dr. Linley Wolfe interviews Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis, about GLP-1 receptor agonist medications (commonly known as Ozempic, Wegovy, and similar drugs) and their implications for pregnancy. The discussion covers how these medications work, their dramatic effects on weight loss and diabetes management, and the emerging phenomenon of "Ozempic babies" - unintended pregnancies occurring in women taking these medications. Dr. Brackney provides guidance on when to discontinue these medications before conception, discusses limited safety data in pregnancy, and explains what monitoring is recommended for women who become pregnant while taking GLP-1s. Both physicians share their personal experiences with these medications and express hope for future research on postpartum use.Episode Highlights00:00:04: Welcome to Healthy Mom, Healthy Baby Tennessee podcast, brought to you by the Tennessee Initiative for Perinatal Quality Care (TIPQC), which exists to improve health outcomes for mothers and infants in Tennessee 00:00:46: Dr. Linley Wolfe introduces Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis who has been practicing as a perinatologist for three years after working as a general OB-GYN for nine years00:01:32: Dr. Brackney describes her passion for caring for women with complex pregnancies and helping them find joy during challenging times00:02:03: Dr. Wolfe introduces the topic of GLP-1 medications, noting they have been revolutionary for people struggling with weight00:02:38: Dr. Brackney explains that GLP-1 receptor agonists work by activating glucagon-like peptide one receptors, regulating blood sugar, reducing appetite, and slowing digestion through multiple mechanisms00:03:46: Discussion of how GLP-1 medications have been around for diabetes treatment but have been increasingly used for weight loss over the last four to five years00:04:04: Dr. Brackney notes these medications are also being used for patients with cardiovascular conditions and kidney disease, showing decreased complications00:04:28: Dr. Wolfe mentions recent approval for people who are overweight with sleep apnea, predicting more indications will emerge00:04:42: Cost identified as one of the biggest barriers to these medications becoming more popular00:05:01: Dr. Brackney reports that semaglutide and tirzepatide show potential for over 10% weight loss, while liraglutide shows 5-15% total weight loss00:05:49: Discussion of side effects, with nausea and constipation being the most common, though they are treatable and many people adjust over time00:06:09: Dr. Wolfe asks about common brand names versus generic names for listener clarity00:06:25: Dr. Brackney lists brand names including Ozempic, Wegovy, Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), and Mounjaro (tirzepatide)00:07:02: Discussion of compounded medications versus manufacturer medications, with Dr. Brackney noting compounded versions are not FDA-regulated and therefore not considered as safe00:07:55: Dr. Wolfe transitions to discussing pregnancy and the phenomenon of "Ozempic babies"00:08:51: Dr. Brackney explains that obesity reduces fertility, with obese women having three times higher risk of infertility and 40% higher miscarriage rates00:10:28: Discussion of how GLP-1 medications may interfere with contraceptive distribution in the body due to slowed gastric emptying00:11:04: Dr. Wolfe summarizes that better overall health, weight loss, and potential contraceptive interference all contribute to "Ozempic babies"00:11:27: Dr. Brackney recommends discontinuing GLP-1 medications at least one to two months before trying to get pregnant, noting limited data on ideal timing00:12:38: Discussion of the lack of...

GLP-1 drugs that are commonly used to treat diabetes and obesity, like Ozempic and Wegovy – are in big demand. And they’re going to be more affordable. The Trump administration recently negotiated deals to lower the prices of these drugs. It seems like some details still need to be ironed out…. but from the looks of it, many Americans who use Medicare will be able to access GLP-1s at a fraction of their original cost. According to one of the deals, some Medicare patients will be able to get GLP-1s for a $50 copay. So it’s safe to assume as costs come down, these drugs are only going to get even more popular…. And we want to know more about them. In this latest “ask a doctor” segment, we’re asking two physicians to answer all of our burning questions. GUESTS: Dr. Scott Hagan, an associate professor of medicine at the University of Washington School of Medicine, who studies obesity. Dr. Mara Gordon, a family physician based in Philadelphia. She also writes about the culture of medicine and authors the “Real Talk With a Doc” column for NPR. RELATED LINKS: Medicare negotiated lower prices for 15 drugs, including 71% off Ozempic and Wegovy : Shots - Health News : NPR Ozempic is making me rethink how to be a body-positive doctor : Shots - Health News : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

Los fármacos adelgazantes se han convertido en un fenómeno global. Ozempic sobre todo, pero Wegovy, Mounjaro… son nombres que ya se escuchan por todas partes. Mientras el sobrepeso y la obesidad crecen, también lo hacen los trastornos de la alimentación, la gordofobia y el culto a la imagen. Y quienes pueden permitírselo —porque las dosis de solo un mes pueden costar entre 200 y 400 euros, y el tratamiento puede alargarse muchos— están comprando estos medicamentos, en algunos casos en el mercado negro y sin receta ni necesidad clínica. En plena fiebre por estos medicamentos, la Organización Mundial de la Salud ha publicado una guía que marca cómo deben usarse: ya los clasificaba como esenciales para personas con diabetes, ahora los amplía en casos de obesidad. No los rechaza, para algunas personas pueden ser una herramienta útil, aunque no los indica para todo el mundo ni en ningún caso como tratamiento exclusivo ni sin seguimiento médico. Y advierte de que no pueden quedar solo al alcance de los que tengan el dinero suficiente para pagarlos. Intervienen Mario Fontán, epidemiólogo social y asesor de la Secretaría de Estado del Ministerio de Sanidad, y Lucía Franco, periodista de EL PAÍS que ha investigado el mercado negro de los fármacos adelgazantes y aporta testimonios de vendedores. CRÉDITOS Realiza: Belén Remacha Presenta: Ana Fuentes Diseño de sonido: Nicolás Tsabertidis Coordina: José Juan Morales Dirige: Ana Alonso Edición: Ana Ribera Sintonía: Jorge Magaz Si tienes quejas, dudas o sugerencias, escribe a defensora@elpais.es o manda un audio a +34 649362138 (no atiende llamadas). La OMS reconoce los fármacos adelgazantes como esenciales para la humanidad: “Deben ser accesibles universalmente” De Andorra a Gibraltar, el mercado negro de Ozempic explota su éxito: “Son los productos más demandados del mundo"

In one of our most eye-opening conversations yet, Bo Brabo and Luke Carignan sit down with clinical pharmacist Langley Kyle to unpack the truth behind GLP-1 medications—Wegovy, Ozempic, Zepbound, tirzepatide, and their compounded counterparts. Whether you're an HR leader, benefits strategist, or simply trying to understand why GLP-1s dominate workplace conversations, this episode breaks it all down with clarity, expertise, and a surprising amount of laughter.From skyrocketing utilization to social-media-driven demand, Langley reveals what she's seeing across employer plans nationwide…and what's coming next.

If you've ever wondered what nutrition on a GLP-1 like Ozempic®, Wegovy®, or Mounjaro®, might look like, this episode is for you! Registered dietitian and lead dietitian for the Mayo Clinic Diet®, Tara Schmidt, joins us to share her expertise on why your habits matter just as much as the medication when it comes to weight loss. She shares what she tells her patients about appetite changes, why fatigue often hits around the three-month mark, and what might happen when you stop taking the medication. She also shares her recommendations on protein intake (spoiler: you might need less than you think), and meals that can help keep your energy up, maintaining muscle, and managing side effects like nausea. Care Experts is a weekly podcast by CareCredit where we sit down with doctors and experts who give information, tips and insight into healthcare treatments and procedures. Check in every Wednesday for new episodes at carecredit.com/careexperts or follow on your favorite podcast app. CareCredit is a health, wellness and personal care credit card that has helped millions of people with promotional financing options and is accepted at hundreds of thousands of provider and retail locations nationwide. Learn more at carecredit.com.

Når Lucas Skræddergaard kom ind i et lokale, kunne han se noget fare hen over de andres ansigter. Afsky. Som om de havde set noget ulækkert. De så i hans retning, men det var ikke ham de fik øje på, det var hans 177 kilo. Han var fed. Så fed at en fremmed mand en sommerdag slog en is ud af hånden på ham. Så fed at det var svært at få et job, og at kærester var noget andre mennesker havde. Så blev han opereret, fik WeGovy og tabte sig – og når han kommer ind i et lokale i dag, sker der noget helt andet. Det fortæller dagens gæst, Lucas Skræddergaard, om i dette afsnit af 'Du lytter til Politiken'.See omnystudio.com/listener for privacy information.

Popular GLP-1 medications like Ozempic, Wegovy, and Zepbound aren’t just transforming weight loss. They’re also changing our intimate lives in surprising ways. In today’s show, we’re diving into results from a new national study finding that a majority of people taking one of these medications reported a change in their sex and dating lives, for better or for worse. My guest is Dr. Amanda Gesselman a research scientist and head of the VIBES research team at the Kinsey Institute at Indiana University. Digital intimacy is a major focus of her research, including how people use tools like camsites, AI companions, dating apps, and social media to navigate connection and desire. Some of the specific topics we explore in this episode include: What specific changes are people noticing in their dating lives as a result of taking one of these drugs? Why does weight loss seem to be benefiting men more than women when it comes to dating? How do GLP-1 medications affect sexual health and function? And is it different for men and women? Are people taking GLP-1 medications worried about social judgement? To learn more, you can read a brief report about the study here. Got a sex question? Send me a podcast voicemail to have it answered on a future episode at speakpipe.com/sexandpsychology. *** Thank you to our sponsors!  Firmtech’s Tech Ring will help you to track your sexual health–and keep it up. Visit myfirmtech.com/justinlehmiller and use code JUSTIN15 for 15% off your purchase.  The Kinsey Institute is where the world turns to understand sex and relationships. You can help continue its expert-led research by donating to the Kinsey Institute Research Fund. Learn more and make a donation here: https://give.myiu.org/centers-institutes/I380010749.html  *** Want to learn more about Sex and Psychology? Click here for previous articles or follow the blog on Facebook, Twitter, or Bluesky to receive updates. You can also follow Dr. Lehmiller on YouTube and Instagram. Listen and stream all episodes on Apple, Spotify, or Amazon. Subscribe to automatically receive new episodes and please rate and review the podcast! Credits: Precision Podcasting (Podcast editing) and Shutterstock/Florian (Music). Image created with Canva; photos used with permission of guest.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk, the pharmaceutical company behind popular GLP-1 medications like Wegovy and Ozempic, recently announced that its phase 3, two-year trial examining GLP-1 medications for Alzheimer's failed to produce a significant reduction in disease progression.While these results are discouraging, they may have revealed something vital about Alzheimer's treatment.In this video, Dr. Bret Scher breaks down the recent failure of Novo Nordisk's evoke and evoke+ trials and what it teaches us about the limitations of a drug-only approach to Alzheimer's treatment.Key topics covered:Why GLP-1s may not be enough for Alzheimer'sThe link between glucose metabolism and brain energy failureHow ketones offer an alternative fuel for the brainEarly research on ketogenic therapy for cognitive impairmentWhy nutritional interventions deserve more scientific attentionWith Alzheimer's affecting millions and costing billions, it's time to shine a light on metabolic strategies that directly support brain energy, reduce inflammation, and improve cognitive function.

Weight loss drugs have once again dominated health headlines.The World Health Organization has endorsed Ozempic-type drugs for long-term obesity treatment, while Australia's TGA has issues new safety alerts - so what's going on here? Plus, we dive into the contentious Oxford Word of the Year, and why it was some people raging... literally. And in headlines today, A suppression order has been lifted allowing reporting on the dark history of Greg Lynn; Disgraced former political staffer Bruce Lehrmann will learn today whether a an appeal to overturn a court ruling he probably raped colleague Brittany Higgins is successful; Palestinian militant group Hamas says it is handing over the remains of one of the two last hostage bodies still in the Gaza Strip; The Prada Group has officially purchased Milan fashion rival Versace in a 1.25 billion euro ($A2.21 billion) deal; Miley Cyrus is engaged to musician Maxx Morando THE END BITS Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Hosts: Taylah Strano & Claire Murphy Guests: Dr Terri-Lynne South, Chair of RACGP Specific Interests Obesity ManagementMyf Warhurst, cultural commentator & host of The Moment podcast Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Should I take a GLP-1? Real Patient Scenarios and Expert GuidanceTrying to figure out if a GLP-1 medication is right for you can feel overwhelming. With options like Wegovy, Zepbound, Ozempic, and Mounjaro, it's not just about weight—these medications can also support heart health, liver function, sleep, and blood sugar. Understanding who truly benefits takes the guidance of an expert.Joining me today is Danielle Marston, or Dani, a board-certified nurse practitioner specializing in obesity medicine, weight management, and nutrition counseling. Dani holds a certificate of advanced education in obesity medicine through the Obesity Medicine Association and provides comprehensive care at our clinic, Colorado Wake Care at Green Mountain Partners for Health. She's here to explain how GLP-1s work, their benefits, and who they can help the most.Through real patient scenarios and practical advice, Dani shows how obesity care can be personalized, evidence-based, and approachable.Whether you're curious about starting a GLP-1, considering other treatment options, or just trying to understand what's available, this episode gives you a clear roadmap to make informed decisions and find a plan that actually fits your life.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Your Guide to Keeping Blood Sugar in Check A1C Made Simple: Your Guide to Keeping Blood Sugar in CheckFewer meals may prevent Type 2 diabetes, obesityDeep-sleep brain waves are linked to blood sugar controlDrug-Induced Diabetes: Are You at Risk?Popular weight loss drugs Ozempic and Wegovy may cause stomach paralysis, doctors warn https://www.georgebatista.com Spectrum Vibrance: https://collabs.shop/s0emjo The Wellness Company - https://www.twc.health/Batista Wellness Resources - http://www.myvitaminresource.com (Promocode: counterparts - For free shipping) https://rumble.com/user/WellnessTalk https://www.instagram.com/georgebatistajr/ https://open.spotify.com/show/5MvjsMT... https://apple.co/3H39DGK Email:Wellnesstalk@protonmail.com Wellness Resources Since 1985, Wellness Resources has used only the highest quality nutrients, no chemical additives, t Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you. Support the showDisclaimer: The Wellness Talk podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.  

This episode is sponsored by Welbeck - providing beyond better healthcare Today we're getting into the weighty topic of GLP-1 weight-loss drugs. Ozempic, Wegovy, Mounjaro - it's a hot topic with a story in the news about it every week.   We are delighted to be joined by consultant endocrinologist Dr Saira Hameed who cuts through the noise bringing medical facts and who knows this topic inside and out. In this episode Dr Saira is mythbusting and answering all of your questions and ours about weight loss injections. It's a fascinating episode you won't want to miss. In this episode we discuss: The different drugs on offer Who should and should not be taking them Side effects and health risks Who qualifies for NHS treatment Why honesty is imperative  The moral panic and is it “cheating” to take them. To learn more or book an appointment go to: https://onewelbeck.com/consultants/dr-saira-hameed/ To buy her books: https://amzn.eu/d/3FXSB1B      https://amzn.eu/d/bl86fm0 Get 20% off at LondonNootropics.com with the code SELFCARE If you liked this episode and want to be part of the club, come follow us on all our socials:  To Listen To 40ISH - https://podcasts.apple.com/gb/podcast/40ish/id1757876983 To order our book “HAVE YOU TRIED THIS?” click here - Paperback out now!  https://www.amazon.co.uk/Have-You-Tried-This-Only/dp/1801293139/ref=sr_1_2?crid=1O7EA4ZF1O5CS&keywords=have+you+tried+this&qid=1699449028&sprefix=have+you+tried+%2Caps%2C125&sr=8-2 For Our Exclusive Merch - https://self-care-club.myspreadshop.co.uk/ Join Our Private Facebook Group https://www.facebook.com/groups/1115099072702743/?ref=share_group_link Instagram  https://www.instagram.com/selfcareclubpod/ YouTube https://youtube.com/c/SelfCareClub TikTok https://vm.tiktok.com/ZMLnXyS1S/ Email hello@theselfcareclub.co.uk  Website www.theselfcareclub.co.uk Studio production by @launchpodstudios Music by purpleplanet. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.• current cash-pay pricing from major manufacturers• differences between Wegovy, Ozempic, and Zepbound• tighter insurance coverage and prior authorization burden• fears about injections and route-of-administration bias• potential oral GLP-1 timelines and cost impact• framing obesity as a chronic, treatable disease• practical tips to explore HSA or FSA options• how to decide if the monthly cost is worth itSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you've been waiting for a GLP-1 weight loss medication that doesn't require injections, special timing, or refrigeration—this episode is for you. Learn about the groundbreaking oral pill that could hit the market as early as 2026. For years, effective obesity medications have meant needles. But Orforglipron could change everything. In this episode, I break down the science, clinical trial results, and approval timeline for this first-of-its-kind once-daily pill that delivers GLP-1 benefits without the injection barriers. Whether you're needle-averse, struggle with injection site reactions, or simply want more convenient options, this new medication could expand access to life-changing obesity treatment.   Episode Highlights: What makes Orforglipron different from Wegovy, Zepbound, and oral semaglutide Clinical trial results: 12.4% average weight loss over 72 weeks Why this oral pill doesn't require fasting or special timing like other oral GLP-1s The FDA accelerated review process and potential 2026 approval timeline Who benefits most: patients with needle phobia, injection site reactions, or seeking maintenance therapy What to expect regarding insurance coverage and access once approved   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Your Guide to Keeping Blood Sugar in Check A1C Made Simple: Your Guide to Keeping Blood Sugar in CheckFewer meals may prevent Type 2 diabetes, obesityDeep-sleep brain waves are linked to blood sugar controlDrug-Induced Diabetes: Are You at Risk?Popular weight loss drugs Ozempic and Wegovy may cause stomach paralysis, doctors warn https://www.georgebatista.com Spectrum Vibrance: https://collabs.shop/s0emjo The Wellness Company - https://www.twc.health/Batista Wellness Resources - http://www.myvitaminresource.com (Promocode: counterparts - For free shipping) https://rumble.com/user/WellnessTalk https://www.instagram.com/georgebatistajr/ https://open.spotify.com/show/5MvjsMT... https://apple.co/3H39DGK Email:Wellnesstalk@protonmail.com Wellness Resources Since 1985, Wellness Resources has used only the highest quality nutrients, no chemical additives, t Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you. Support the showDisclaimer: The Wellness Talk podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.  

The World Health Organisation has updated its guidelines for their treatment of obesity - and is now recommending GLP-1 drugs, like Ozempic and Wegovy, alongside behavioral therapy. University of Auckland's Professor Peter Shepherd spoke to Ingrid Hipkiss.

My granddaughter suffers from menstrual cramps.  Do you have any suggestions?Do you recommend nicotinamide daily to prevent recurrence of basal cell cancers?What works best to lower fibrinogen?I've been on Ozempic for a year and have diarrhea every morning!Is bypass surgery still being done?Would you recommend Bergamot for fatty liver?

Thanksgiving and overindulgenceA food poisoning incidentObservations on health at ThanksgivingWhat do you think of online sites offering prescriptions for hair loss via a questionnaire?

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027. That will bring the monthly costs of those drugs down from nearly $1,000 to $274. The Centers for Medicare and Medicaid Services also announced price reductions for 14 other drugs. We'll hear more. Plus, can a market economy that uses fake cash help food banks get the food donations they want?

Medicare will get a 71% discount off the list price of Ozempic and Wegovy starting in 2027. That will bring the monthly costs of those drugs down from nearly $1,000 to $274. The Centers for Medicare and Medicaid Services also announced price reductions for 14 other drugs. We'll hear more. Plus, can a market economy that uses fake cash help food banks get the food donations they want?

Rough Week – does not phase bulls! Bitcoin – Bottoming? Let’s take a look at Walmart and Target again Homeowners! Mortgage Reform? PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Short Week - Markets closed on Thursday and short Friday (1pm) - Can't have a down week for TDAY! - Too much table talk - Recession News - Let's take a look at Walmart and Target again - Homeowners! Mortgage Reform? Markets - Rough Week - does not phase bulls! - Bitcoin - Bottoming? - NVDA - China Bound? - NASDAQ Weighting Inflation - Still Up There - They are now pressing for a cut in December (How are we handicapping this?) - All of a sudden the parade of Fed speakers - all seem a bit more dovish. Meanwhile - President Donald Trump on Friday rolled back tariffs on more than 200 food products, including such staples as coffee, beef, bananas and orange juice, in the face of growing angst among American consumers about the high cost of groceries. - oranges, acai berries and paprika to cocoa, chemicals used in food production, fertilizers and even communion wafers. Quantum Stocks GOOD NEWS! - NO Recession risk! - Bessent says inflation due to services economy, not tariffs - Treasury secretary says Republicans should end filibuster in event of another shutdown - Bessent says administration working to lower prices where it can - Banking and insurance,  Software development and cloud services, Tourism, Restaurants and hospitality , Professional services (law, accounting, consulting) Rigging it - NEC Director Kevin Hassett emerges as frontrunner for Fed Chair as President Trump nears decision, according to Bloomberg Weird News - Buried in the NVDA earnings report - Remember back in September, the two companies announced a massive partnership that would include a $100 billion investment over time by Nvidia into OpenAI. - Nvidia said in its quarterly financial filing that there's no guarantee that the company will finalize an agreement with OpenAI. - Soooooo - is this all hot air???? More NVDA - Here we go. Another reversal - President Donald Trump will make a final decision on whether to allow Nvidia Corp. to sell advanced artificial intelligence chips to China. - The decision involves weighing the promotion of economic expansion against protecting national security, according to US Commerce Secretary Howard Lutnick. ------ Read that again - money versus national security - Allowing the sales would mark a significant easing of restrictions imposed in 2022 to prevent Beijing and its military from accessing the most powerful US technologies. Chip in question: H200 - Had some discussions about this - might as well as they will just get it on their own and this way we can control. (On the other hand, they have a long history of outsmarting us) EVEN MORE - NVIDIA issues memo to CNBC: The company said "We are not aware of any claims that NVDA has improperly capitalized operating expenses. Several commentators allege that customers have overstated earnings by extending GPU depreciation schedules beyond economic useful life" | - The tip of the Iceberg - this is what Michael Burry has been pressing..... HPQ Earnings - HP Inc. beats by $0.01, reports revs in-line; guides Q1 EPS in-line; guides FY26 EPS below consensus; increases dividend; announces company-wide initiative, includes job cuts - Stock down 6% Amazon - The Spend keeps going... - Amazon.com Inc. says it will spend as much as $50 billion expanding its capacity to provide artificial intelligence and high-performance computing services to US government entities. - Amazon Web Services plans to break ground next year on what will ultimately be 1.3 gigawatts of additional capacity across data centers designed for federal agencies, the company said in a blog post on Monday. Google/Berkshire - Berkshire Hathaway revealed a $4.3 billion stake in Google parent Alphabet (GOOGL.O), further reduced its stake in Apple - Google on a ramp since - new Gemini and... - Meta Platforms Inc. is in talks to spend billions on Google's AI chips, adding to a months long share rally as the search giant has made the case it can rival Nvidia Corp. as a leader in artificial intelligence technology. - Meta is in discussions to use the Google chips — known as tensor processing units, or TPUs — in data centers in 2027, and may rent chips from Google's cloud division next year. - Really smart people at Berkshire? What did they know? NASDAQ 100 - Uninvestable? - Top 10 stocks are over 70% weighting - SP500 top 10 stocks = 38% - This is not a diversified approach any longer - Coming up on next week's TDI Podcast - Howard Silverblatt - S&P Dow Jones - Keeper of the data Something They Don't Want You To Know - “Magnificent 7” Companies Reported Lowest Earnings Growth Since Q1 2023 - With NVIDIA reporting actual results for Q3 on November 19, all the companies in the “Magnificent 7” have now reported earnings for the third quarter. - “Magnificent 7” companies reported actual earnings growth of 18.4% for the third quarter. This earnings growth rate is below the average earnings growth rate of 28.8% for these seven companies over the previous four quarters. Novo Nordisk - Pummeled - Shares of Novo Nordisk on Monday fell to a four-year low after the Danish pharmaceutical company said a highly anticipated trial for Alzheimer's disease failed to meet its main goal. - The trial tested whether semaglutide — the active ingredient in Novo's blockbuster diabetes and weight loss drugs Ozempic and Wegovy — helped slow progression for Alzheimer's disease. -While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in two separate trials, this did not translate into a delay of disease progression, Novo said in a statement Monday. The goal had been to slow patients' cognitive decline by at least 20%. - Reminiscent of Pfizer - after Covid shot had noting left... Bitcoin - Live by the sword.... - iShares Bitcoin Trust had $2.2 billion in net outflows in November, according to WSJ - Big month of losses for crypto - not too much mention and support by Whitehouse - Selling started - coincidentally with  the pardon of Changpeng Zhao, the convicted founder of the Binance Remember DOGE - DOGE disbanded eight months ahead of scheduled end in July 2026 - Former DOGE employees take new roles in administration - Elon Musk initially led DOGE, promoting its work on social media - bagged out when stock tanked - DOGE claimed to have slashed tens of billions of dollars in expenditures, but it was impossible for outside financial experts to verify that because the unit did not provide detailed public accounting of its work. Walmart - Walmart raised its sales and earnings outlook last week as the retailer posted revenue gains in its fiscal third quarter, driven by double-digit e-commerce growth and new customers across incomes. - The retailer said it expects full-year net sales to climb between 4.8% and 5.1%, up from its previous expectations of 3.75% to 4.75%. - It said it expects its adjusted earnings per share to range from $2.58 to $2.63, a slight raise from its prior range of $2.52 to $2.62. - Stock went vertical ---- - Much different story than Target - WMT up 16% YTD - TGT down 37% Beef Prices - Not Going Down - Tyson Foods stock rallying on Monday following the company's official confirmation that it will shutter its Lexington, Nebraska, beef facility, a strategic move that validates earlier reporting by The Wall Street Journal. - The decision comes as the meat and poultry giant grapples with historically low U.S. cattle inventories, which have severely compressed margins and led to a reported $426 mln adjusted operating loss for its beef segment in FY25.| - Seems that investors like this decisive cost-cutting measure, viewing the capacity reduction as a necessary step toward restoring profitability in a challenging commodity environment. Japan - Japanese Prime Minister Sanae Takaichi's cabinet approved a 21.3 trillion yen ($135.40 billion) economic stimulus package last Friday, marking the first major policy initiative under the new leader, who has pledged to pursue expansionary fiscal measures. - The package includes general account outlays of 17.7 trillion yen, far exceeding the previous year's 13.9 trillion yen and representing the largest stimulus since the COVID pandemic. It will also include 2.7 trillion yen in tax cuts. - Problem is that the Yen is sliding and intervention is imminent - Inflation issue and they will make it worse with this stimulus Larry Summers? - Epstein Files - IS there any There , There? Talk about a 50 Year Mortgage? - Such a bad idea  - and these boneheads think it is smart - 30-Year Mortgage Monthly Payment: $1,610.46 Total Payment: $579,767.35 Total Interest Paid: $279,767.35 - 50-Year Mortgage Monthly Payment: $1,362.42 Total Payment: $817,449.78 Total Interest Paid: $517,449.78 Thanksgiving Costs 2025 National Average (American Farm Bureau Survey) - 2025: $55.18 for a classic dinner for 10 people (about $5.52 per person) - 2024: $58.08 for the same meal - Change: Down 5% year-over-year This is the third consecutive annual decline since the record high of $64.05 in 2022. Key Drivers Turkey prices dropped sharply: A 16-pound frozen turkey averages $21.50, down 16% from 2024. Sides are mixed: Dinner rolls and stuffing are cheaper (down 14.6% and 9%). Sweet potatoes and veggie trays are much higher (up 37% and 61%). Regional Differences South: $50.01 (most affordable) West: $61.75 (most expensive) Classic Meal for 10 ($55???????) 16-pound turkey (frozen, whole) Stuffing mix (14 ounces) Sweet potatoes (3 pounds) Rolls (12-count package) Peas (1 pound) Cranberries (12 ounces) Carrots and celery (for a veggie tray) Pumpkin pie mix (30 ounces) Pie shells (two, 9-inch) Whipping cream (half pint) Milk (1 gallon) - Love the Show? Then how about a Donation? THE CTP FOR: iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter